Snapshot of the Global Therapeutic Landscape of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) to Deliver by Research Available at The Market Reports

Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Source: https://www.themarketreports.com/report/lebers-hereditary-optic-neuropathy-leber-optic-atrophy-pipeline-review-h2-2018

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) therapeutics and enlists all their major and minor projects.

Purchase this report at: https://www.themarketreports.com/report/buy-now/1280211

Reasons To Buy

  • Find and recognize significant and varied types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Alkeus Pharmaceuticals Inc
  • Bactevo Ltd
  • Biovista Inc
  • Fortify Therapeutics Inc
  • GenSight Biologics SA
  • Ixchel Pharma LLC
  • Khondrion BV
  • Mitobridge Inc
  • Mitotech SA
  • Santhera Pharmaceuticals Holding AG
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Inc

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1280211

Posted by on Friday September 21 2018, 9:05 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

Featured Press Releases

Log in